Treatment of chronic myelogenous leukemia with bone marrow transplantation.

No abstract is available for this paper.

• Publication year

  1990

• Venue

  Hematology/Oncology Clinics of North America

• Publication date

  1990-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S0889-8588(18)30477-5PMID 2193013
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Rearrangement and expression of p53 in the chronic phase and blast crisis of chronic myelogenous leukemia.

  1990cited by this paper
• DNA-RFLP Analysis: HLA-DR Beta Workshop Report

  1989cited by this paper
• Nomenclature for HLA-RFLP

  1989cited by this paper
• Influence of acute and chronic graft-versus-host disease on relapse and survival after bone marrow transplantation from HLA-identical siblings as treatment of acute and chronic leukemia.

  1989cited by this paper
• Rearrangements in the p53 gene in Philadelphia chromosome positive chronic myelogenous leukemia.

  1989cited by this paper
• No correlation between locations of bcr breakpoints and clinical states in Ph1-positive CML patients.

  1989cited by this paper
• Detection of Philadelphia chromosome-positive cells by the polymerase chain reaction following bone marrow transplant for chronic myelogenous leukemia

  1989cited by this paper
• Effect of HLA compatibility on engraftment of bone marrow transplants in patients with leukemia or lymphoma.

  1989cited by this paper
• Analysis of BCR‐ABL mRNA in chronic myelogenous leukemia patients and identification of a new BCR‐related sequence in human DNA

  1989cited by this paper
• Indications for marrow transplantation in chronic myelogenous leukemia.

  1989cited by this paper
• Alterations in the p53 gene and the clonal evolution of the blast crisis of chronic myelocytic leukemia.

  1989cited by this paper
• Detection by enzymatic amplification of bcr-abl mRNA in peripheral blood and bone marrow cells of patients with chronic myelogenous leukemia.

  1989cited by this paper
• Technical modifications in hyperfractionated total body irradiation for T-lymphocyte deplete bone marrow transplant.

  1989cited by this paper
• Detection of two alternative bcr/abl mRNA junctions and minimal residual disease in Philadelphia chromosome positive chronic myelogenous leukemia by polymerase chain reaction.

  1989cited by this paper
• Successful autografting in chronic myeloid leukaemia after maintenance of marrow in culture.

  1989cited by this paper
• Detection of Philadelphia chromosome-positive cells by the polymerase chain reaction following bone marrow transplant for chronic myelogenous leukemia.

  1989cited by this paper
• Population Analysis of Class I HLA Antigens by One-Dimensional Isoelectric Focusing Gel Electrophoresis: Workshop Summary Report

  1989cited by this paper
• The use of unrelated bone marrow donors in the treatment of patients with chronic myelogenous leukemia: experience of four marrow transplant centers.

  1989cited by this paper
• Upper and lower time limits in the decision to recommend marrow transplantation for patients with chronic myelogenous leukaemia

  1988cited by this paper
• Molecular abnormalities of bcr and c-abl in chronic myelogenous leukemia associated with a long chronic phase.

  1988cited by this paper
• Transformation of an interleukin 3-dependent hematopoietic cell line by the chronic myelogenous leukemia-specific P210bcr/abl protein.

  1988cited by this paper
• Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Increased risk for relapse associated with T-cell depletion.

  1988cited by this paper
• Frequency analysis of cytotoxic T lymphocyte precursors--possible relevance to HLA-matched unrelated donor bone marrow transplantation.

  1988cited by this paper
• Bone marrow transplantation for chronic myeloid leukaemia in first chronic phase: importance of a graft‐versus‐leukaemia effect

  1988cited by this paper
• The site of the breakpoint within the bcr is a prognostic factor in Philadelphia-positive CML patients.

  1988cited by this paper
• T CELL DEPLETION WITH CAMPATH‐1 IN ALLOGENEIC BONE MARROW TRANSPLANTATION

  1988cited by this paper
• Use of the BCR probe to demonstrate extramedullary recurrence of CGL with a T cell lymphoid phenotype following bone marrow transplantation.

  1988cited by this paper
• Immunoglobulin and T-cell receptor gene rearrangement in blast crisis of chronic myelocytic leukemia.

  1988cited by this paper
• Cytogenetic events after bone marrow transplantation for chronic myeloid leukemia in chronic phase.

  1988cited by this paper
• Detection of minimal residual bcr/abl transcripts by a modified polymerase chain reaction.

  1988cited by this paper
• Use of minisatellite DNA probes for recognition and characterization of relapse after allogeneic bone marrow transplantation

  1988cited by this paper
• Preliminary characterization of functional residual host-type T lymphocytes following conditioning for allogeneic HLA-matched bone marrow transplantation (BMT).

  1988cited by this paper
• Prognostic significance of cytogenetic abnormalities in patients with chronic myelogenous leukemia.

  1988cited by this paper
• The location of breakpoints within the breakpoint cluster region (bcr) of chromosome 22 in chronic myeloid leukemia.

  1988cited by this paper
• Prognostic significance of additional cytogenetic abnormalities at diagnosis of Philadelphia chromosome-positive chronic granulocytic leukemia.

  1988cited by this paper
• Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Increased risk for relapse associated with T-cell depletion.

  1988cited by this paper
• Prevention of graft-versus-host disease by ex vivo T cell depletion: reduction in graft failure with augmented total body irradiation.

  1988cited by this paper
• Irradiated donor buffy coat following T cell-depleted bone marrow transplants.

  1988cited by this paper
• HLA-identical marrow transplantation during accelerated-phase chronic myelogenous leukemia: analysis of survival and remission duration.

  1988cited by this paper
• Relapse after allogeneic bone marrow transplantation for Philadelphia chromosome positive chronic myeloid leukemia: cytogenetic analysis of 24 patients.

  1988cited by this paper
• Competition between recipient and donor cells after bone marrow transplantation for chronic myeloid leukaemia

  1988cited by this paper
• Prospective confirmation of a prognostic classification for Ph + chronic myeloid leukaemia

  1988cited by this paper
• bcr genes and transcripts.

  1988cited by this paper
• Interferon alpha-2b as therapy for Ph'-positive chronic myelogenous leukemia: a study of 82 patients treated with intermittent or daily administration.

  1988cited by this paper
• PROBABILITY OF FINDING HLA‐MATCHED UNRELATED MARROW DONORS

  1988cited by this paper
• Allogeneic marrow grafting with partially mismatched, unrelated marrow donors.

  1988cited by this paper
• The molecular genetics of Philadelphia chromosome-positive leukemias.

  1988cited by this paper
• Definition of the accelerated phase of chronic myelogenous leukemia.

  1988cited by this paper
• Molecular analysis of relapse in chronic myeloid leukemia after allogeneic bone marrow transplantation.

  1987cited by this paper
• The first intron in the human c-abl gene is at least 200 kilobases long and is a target for translocations in chronic myelogenous leukemia

  1987cited by this paper
• The role of T-cells in preventing relapse in chronic myelogenous leukemia.

  1987cited by this paper
• Therapy of chronic myelogenous leukemia with allogeneic bone marrow transplantation.

  1987cited by this paper
• Bone marrow transplantation for leukemia following a new busulfan and cyclophosphamide regimen.

  1987cited by this paper
• Total body irradiation and high-dose etoposide: a new preparatory regimen for bone marrow transplantation in patients with advanced hematologic malignancies [published erratum appears in Blood 1987 Jun;69(6):1789]

  1987cited by this paper
• Therapy of chronic myelogenous leukemia with recombinant interferon-gamma.

  1987cited by this paper
• Total body irradiation and high-dose etoposide: a new preparatory regimen for bone marrow transplantation in patients with advanced hematologic malignancies.

  1987cited by this paper
• Bone marrow transplantation for leukemia following a new busulfan and cyclophosphamide regimen

  1987cited by this paper
• Clinical and prognostic features of patients with philadelphia chromosome‐positive chronic myelogenous leukemia and extramedullary disease

  1987cited by this paper
• Unrelated donor bone marrow transplantation therapy for chronic myelogenous leukemia.

  1987cited by this paper
• Loss of myeloid differentiation antigens precedes blastic transformation in chronic myelogenous leukemia.

  1987cited by this paper
• HAEMOPOIETIC RECOVERY FROM Ph1 POSITIVE CHRONIC GRANULOCYTIC LEUKAEMIA

  1987cited by this paper
• In vitro transformation of immature hematopoietic cells by the P210 BCR/ABL oncogene product of the Philadelphia chromosome.

  1987cited by this paper
• Effect of recombinant gamma interferon on chronic myelogenous leukemia bone marrow progenitors.

  1987cited by this paper
• Analysis of P210bcr-abl tyrosine protein kinase activity in various subtypes of Philadelphia chromosome-positive cells from chronic myelogenous leukemia patients.

  1987cited by this paper
• Evidence that the phl gene encodes a 160,000-dalton phosphoprotein with associated kinase activity.

  1987cited by this paper
• Immune interventions in disease.

  1987cited by this paper
• A prospective randomized study of acute graft-v-host disease in 107 patients with leukemia: methotrexate/prednisone v cyclosporine A/prednisone.

  1987cited by this paper
• TRIPLE CHIMAERISM AFTER ALLOGENEIC BONE MARROW TRANSPLANTATION FOR PHILADELPHIA CHROMOSOME POSITIVE CHRONIC GRANULOCYTIC LEUKAEMIA

  1987cited by this paper
• Clinical investigation of human alpha interferon in chronic myelogenous leukemia.

  1987cited by this paper
• Competitive survival/proliferation of normal and Ph1‐positive haemopoietic cells

  1986cited by this paper
• Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia.

  1986cited by this paper
• Prognostic assessment of various parameters in chronic myeloid leukemia

  1986cited by this paper
• Reconstitution of haemopoietic system with autologous marrow taken during relapse of acute myeloblastic leukaemia and grown in long-term culture.

  1986cited by this paper
• Histocompatible unrelated volunteer donors compared with HLA nonidentical family donors in marrow transplantation for aplastic anemia and leukemia.

  1986cited by this paper
• The effects of splenectomy on engraftment and platelet transfusion requirements in patients with chronic myelogenous leukemia undergoing marrow transplantation

  1986cited by this paper
• Bone marrow transplantation for patients with chronic myeloid leukemia.

  1986cited by this paper
• Treatment of donor bone marrow with monoclonal anti-T-cell antibody and complement for the prevention of graft-versus-host disease. A prospective, randomized, double-blind trial.

  1986cited by this paper
• Ph1 negative haematological chimaerism after marrow transplantation in Ph1 positive chronic granulocytic leukaemia

  1986cited by this paper
• Interstitial pneumonitis after bone marrow transplantation. Assessment of risk factors.

  1986cited by this paper
• Variables influencing the timing of marrow transplantation in patients with chronic myelogenous leukemia.

  1986cited by this paper
• Marrow transplantation for the treatment of chronic myelogenous leukemia.

  1986cited by this paper
• Adverse effect of severe marrow fibrosis on hematologic recovery after chemoradiotherapy and allogeneic bone marrow transplantation.

  1986cited by this paper
• Bone marrow transplantation for patients with chronic myeloid leukaemia: T-cell depletion with Campath-1 reduces the incidence of graft-versus-host disease but may increase the risk of leukaemic relapse.

  1986cited by this paper
• Monoclonal antibodies to promote marrow engraftment and tissue graft tolerance

  1986cited by this paper
• Hematologic remission and cytogenetic improvement induced by recombinant human interferon alpha A in chronic myelogenous leukemia.

  1986cited by this paper
• Effect of splenectomy before bone-marrow transplantation on survival in chronic granulocytic leukaemia.

  1985cited by this paper
• PREVENTION OF GRAFT-VERSUS-HOST DISEASE IN ALLOGENEIC BONE-MARROW TRANSPLANTATION FOR LEUKEMIA BY T-CELL DEPLETION INVITRO PRIOR TO TRANSPLANTATION

  1985cited by this paper
• Marrow transplantation from related donors other than HLA-identical siblings.

  1985cited by this paper
• GRAFT‐VERSUS‐LEUKAEMIA EFFECT FOLLOWING ALLOGENEIC BONE MARROW TRANSPLANTATION

  1985cited by this paper
• Intensive combination chemotherapy (ROAP 10) and splenectomy in the management of chronic myelogenous leukemia.

  1985cited by this paper
• Suppression of clonal evolution in two chronic myelogenous leukaemia patients treated with leucocyte interferon

  1985cited by this paper
• Chronic myelogenous leukemia: a multivariate analysis of the associations of patient characteristics and therapy with survival.

  1985cited by this paper
• In vitro restoration of polyclonal hematopoiesis in a chronic myelogenous leukemia after in vitro treatment with 4-hydroperoxycyclophosphamide.

  1985cited by this paper
• Leukaemic transformation of engrafted bone marrow cells

  1985cited by this paper
• Prognostic discrimination among younger patients with chronic granulocytic leukemia: relevance to bone marrow transplantation.

  1985cited by this paper
• T cells and probably B cells arise from the malignant clone in chronic myelogenous leukemia.

  1985cited by this paper
• Structural organization of the bcr gene and its role in the Ph′ translocation

  1985cited by this paper
• A clinical trial of in vitro depletion of T cells in donor marrow for prevention of acute graft-versus-host disease

  1985cited by this paper
• How does bone-marrow transplantation cure leukaemia?

  1984cited by this paper
• Allogeneic bone marrow transplantation as treatment for accelerating chronic myelogenous leukemia.

  1984cited by this paper

• with chronic myelogenous leukemia in chronic phase preparatory regimen for bone marrow transplantation for 94 patients Fractionated total-body irradiation and high-dose etoposide as a

  2011cites this paper
• Evaluation of the Bone Marrow After Therapy

  2011cites this paper
• Sjögren-like syndrome after bone marrow transplantation.

  2008cites this paper
• Illustrated pathology of the bone marrow

  2006cites this paper
• Regulation of survivin expression through Bcr-Abl/MAPK cascade: targeting survivin overcomes imatinib resistance and increases imatinib sensitivity in imatinib-responsive CML cells.

  2006cites this paper
• Illustrated Pathology of the Bone Marrow: Post-therapy bone marrow changes

  2006cites this paper
• Allosterically Controlled Ribozymes as Artificial Ribonucleases

  2004cites this paper
• Allosterically controllable maxizymes for molecular gene therapy.

  2002cites this paper
• Allosterically controllable maxizyme-mediated suppression of progression of leukemia in mice.

  2001cites this paper
• Oncogene inactivation in a mouse model

  2000cites this paper
• Early detection of relapse by hypermetaphase fluorescence in situ hybridization after allogeneic bone marrow transplantation for chronic myeloid leukemia.

  2000cites this paper
• Allosterically controllable maxizymes cleave mRNA with high efficiency and specificity.

  2000cites this paper
• Inhibition of bcr-abl Oncogene Expression by Novel Deoxyribozymes (DNAzymes)

  1999cites this paper
• Effect of Retrovirus and Adenovirus Mediated Interferon Gene Transfer on Hematopoietic Progenitor Cell Growth

  1999cites this paper
• Quality of IL-3 and G-CSF-mobilized peripheral blood stem cells in patients with early chronic phase CML

  1998cites this paper
• Retrovirus and Adenovirus-Mediated Interferon Gene Transfer into Hematopoietic Stem Cells (CD 34+) of Normal and Chronic Myelogenous Leukemia

  1998cites this paper
• Gene therapy for chronic myelogenous leukemia (CML): a retroviral vector that renders hematopoietic progenitors methotrexate-resistant and CML progenitors functionally normal and nontumorigenic in vivo.

  1997cites this paper
• Cytogenetics of chronic myelogenous leukaemia.

  1997cites this paper
• Acute Leukemias VII. Experimental Approaches and Novel Therapies. International Symposium. Munster, Germany, February 22-26, 1997. Abstracts.

  1997cites this paper
• Usefulness of detection of minimal residual disease by ‘hypermetaphase’ fluorescent in situ hybridization after allogeneic BMT for chronic myelogenous leukemia

  1997cites this paper
• Adenovirus Mediated Alpha Interferon (IFN‐α) Gene Transfer into CD34+ Cells and CML Mononuclear Cells

  1997cites this paper
• Gene therapy for chronic myelogenous leukemia (CML): a retroviral vector that renders hematopoietic progenitors methotrexate-resistant and CML progenitors functionally normal and nontumorigenic in vivo

  1997cites this paper
• Bone Marrow Transplantation for Cancer - An Update.

  1996cites this paper
• [Busulfan versus busulfan-interferon as maintenance therapy in chronic myeloid leukemia].

  1996cites this paper
• Childhood leukemias.

  1995cites this paper
• Leukemias, myeloma, and other lymphoreticular neoplasms

  1995cites this paper
• Deficit of T-cell recovery after allogeneic bone marrow transplantation in chronic myeloid leukemia patients.

  1995cites this paper
• Corticosteroids as adjunctive therapy for diffuse alveolar hemorrhage associated with bone marrow transplantation. University of Nebraska Medical Center Bone Marrow Transplant Group.

  1994cites this paper
• Fractionated total-body irradiation and high-dose etoposide as a preparatory regimen for bone marrow transplantation for 94 patients with chronic myelogenous leukemia in chronic phase.

  1994cites this paper
• Prolonged remission after blastic phase relapse of chronic myelogenous leukemia following BMT.

  1994cites this paper
• Chronic myelogenous leukemia: a concise update.

  1993cites this paper
• Bone marrow transplantation of chronic myelogenous leukemia in chronic phase: evaluation of risks and benefits.

  1992cites this paper
• [Health status and late complications following allogeneic bone marrow transplantation. A review].

  1991cites this paper